Study Shows Bone Medication Infuse Increases Cancer Risk

Written By: Rheingold, Valet, Rheingold, Ruffo & Giuffra LLP

Nov 29, 2011

It was reported at a national conference of spine surgeons Thursday, November 3rd that there is an increased cancer risk with a certain bone medication. Infuse, a Medtronicproduct, was discovered to increase patient cancer risks when used in high doses during spinal fusion procedures. An analysis led by a Stanford University orthopedic surgeon found that cancer was three to five times more likely to develop in spine surgery patients who received a bone growth stimulating agent as a part of their clinical trial. The cancer was found typically within two to three years after the product was implanted.

Categories:

Don't Settle

for an Average Attorney

- Name:
  
  Please enter your name.
- Phone
  
  This isn't a valid phone number.
- Email:
  
  Please enter your email address.
  
  This isn't a valid email address.
- Are you a new client?
  
  Please make a selection.
- Message
  
  Please enter a message.

Get RGRP On Your Side